Fresenius Medical Care
About: Fresenius Medical Care is the largest dialysis company in the world, treating about 300,000 patients from nearly 3,700 clinics worldwide as of December 2024. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market, creating the world's only fully integrated dialysis business. Services account for about three quarters of sales while the balance is generated from medical technology products that enable dialysis treatments.
Employees: 112,035
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
137% more call options, than puts
Call options by funds: $3.06M | Put options by funds: $1.29M
88% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 16
23% more repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 52
13% more capital invested
Capital invested by funds: $770M [Q4 2024] → $873M (+$103M) [Q1 2025]
5% more funds holding
Funds holding: 188 [Q4 2024] → 198 (+10) [Q1 2025]
0.35% more ownership
Funds ownership: 11.59% [Q4 2024] → 11.94% (+0.35%) [Q1 2025]
100% less funds holding in top 10
Funds holding in top 10: 1 [Q4 2024] → 0 (-1) [Q1 2025]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$30
5%
upside
Avg. target
$30
5%
upside
High target
$30
5%
upside
1 analyst rating
0 positive
0%
1 neutral
100%
0 negative
0%
Truist Securities David Macdonald | 5%upside $30 | Hold Maintained | 12 May 2025 |
Financial journalist opinion
Based on 6 articles about FMS published over the past 30 days
Negative
Zacks Investment Research
1 week ago
Reasons to Add Fresenius Medical Stock to Your Portfolio Now
FMS continues to gain traction on the back of acquisitions & partnerships. A tough regulatory environment raises concerns.
Positive
Zacks Investment Research
1 week ago
Fresenius (FMS) Upgraded to Buy: Here's Why
Fresenius (FMS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Neutral
PRNewsWire
1 week ago
Fresenius Medical Care Begins Broader U.S. Commercialization of 5008X™ CAREsystem, Achieves Key Milestones in Efforts to Introduce High-Volume Hemodiafiltration Dialysis Therapy to Individuals with Kidney Disease in the U.S.
Updated 5008X CAREsystem with Additional Features Receives FDA 510(k) Clearance Company announces first wave of Fresenius Kidney Care clinics in the U.S. to begin offering high-volume hemodiafiltration therapy to dialysis patients Introducing the 5008X CAREsystem and hemodiafiltration kidney replacement therapy is a key pillar of the company's growth strategy BAD HOMBURG, Germany , June 4, 2025 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, today begins the second phase of the company's efforts to introduce high-volume hemodiafiltration (HVHDF) kidney replacement therapy across the United States. The company last week received FDA 510(k) clearance for the updated version of its new, hemodiafiltration-capable 5008X CAREsystem with additional features, a key benchmark enabling the next steps in the company's broader commercialization efforts across the U.S. later this year, followed by a full-scale commercial launch in 2026.
Neutral
PRNewsWire
2 weeks ago
Fresenius Medical Care presents its new research and innovation for kidney care at European Renal Association Congress 2025
Key abstract presentations showcase significant advancements in clinical care, artificial intelligence, and fluid management, demonstrating Fresenius Medical Care's commitment to improving patient outcomes. Top Abstract recognition for "Prevalence and Patterns of Intradialytic Arterial Oxygen Saturation Instability: Observations in a Large U.S. Hemodialysis Cohort," presented in the "Dialysis" category.
Neutral
PRNewsWire
3 weeks ago
Fresenius Medical Care Annual General Meeting: Strong Performance Against Its Strategic Plan Results in Highest Dividend per Share in Its History
Shareholders approved the proposed dividend of 1.44 Euro per share, representing a 21 percent increase year-over-year and marking the highest dividend in the company's history Excellent progress in the company's transformation and turnaround plans continues to strengthen the foundation for sustainable, profitable growth In 2024, organic revenue growth1 was 4 percent, and operating income increased by 18 percent on an outlook base2, coming in at the upper end of the company's outlook The company is well positioned for double digit earnings growth in 2025, translating to an 11-12 percent margin BAD HOMBURG, Germany , May 22, 2025 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for people with kidney disease, continuously executed its strategic plan during the 2024 fiscal year. The success of this transformation is strengthening the foundation for sustainable, profitable growth — both now and in the future.
Positive
Zacks Investment Research
3 weeks ago
Here's Why Fresenius (FMS) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Positive
Zacks Investment Research
1 month ago
Fresenius (FMS) is a Great Momentum Stock: Should You Buy?
Does Fresenius (FMS) have what it takes to be a top stock pick for momentum investors? Let's find out.
Positive
Zacks Investment Research
1 month ago
Fresenius (FMS) is a Top-Ranked Momentum Stock: Should You Buy?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Positive
Zacks Investment Research
1 month ago
5 High-Flying Medical Instrument Stocks to Buy Despite Recent Turmoil
Five high-flying medical instrument stocks are: DXCM, IDXX, NPCE, CLPT, FMS.
Positive
Zacks Investment Research
1 month ago
New Strong Buy Stocks for May 9th
CBNA, FMS, BNTGY, WYY and BCRX have been added to the Zacks Rank #1 (Strong Buy) List on May 9, 2025.
Charts implemented using Lightweight Charts™